The approval is based on a phase 2 trial showing that Libtayo achieved a response in 29% of patients ... although the picture may not be quite so simple. On its own, Keytruda cut the risk of ...

A group of researchers from the NYU Tandon School of Engineering have started a year-long project to create a virtual “twin” ...

The presentation will feature updates from the San Diego County Sheriff and Robert Logan, fire chief of the San Diego Fire-Rescue Department, on emergency response procedures, actions to increase ...

Ferrari posted a picture of Hamilton reclining on two tires with their helmet in his left hand. The post was captioned as: Kyle Larson, the #5 for Hendrick Motorsports had a remarkable 2024 where ...

Lady Gaga has responded to critics of Joker: Folie a Deux (Picture: Axelle/Bauer-Griffin/FilmMagic) A follow-up to the hit 2019 film Joker, the comic book sequel ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed significant ...